HSBC turned bearish on Eli Lilly (LLY), slashing its price target to $850 (stock was at ~$930) and stating investor expectations for weight-loss drugs are "overinflated." Shares fell nearly 6%. The analyst call directly challenges the bullish consensus embedded in the stock price, suggesting significant downside risk if expectations are recalibrated. The specific downgrade and price target cut, coupled with the stock's negative reaction, support a SHORT view based on valuation concerns. Stronger-than-expected drug sales or pipeline updates could reignite bullish sentiment.